Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA advises Benitec Biopharma Ltd to proceed with Hepatitis C trial

Monday, 13 Jan 2014 05:32pm EST 

Benitec Biopharma Ltd:Says that the US Food and Drug Administration (FDA) has advised the company that it may proceed with its 'first in man' clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat Hepatitis C with a single injection.Says this follows the FDA's review of Benitec's Investigational New Drug (IND) application, which was filed on Dec. 6, 2013. 

Company Quote

0.07 +8.97%
4 May 2015